1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
Delayed Nasdaq  -  04:00 2022-06-30 pm EDT
51.43 USD   -0.81%
06/29Novavax to Participate in Vaccines and Related Biological Products Advisory Committee Review of COVID-19 Vaccines Strain Composition
AQ
06/29BioNTech, Pfizer to starting testing universal coronavirus vaccine in H2
RE
06/29Taiwan to receive first doses of Novavax COVID vaccine this week
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EMA Starts Evaluating Use Of Booster Dose Of Nuvaxovid In Adults

05/20/2022 | 09:51am EDT

May 20 (Reuters) - European Medicines Agency:

* EMA: EMA STARTED EVALUATING THE USE OF A BOOSTER DOSE OF NOVAVAX'S COVID-19 VACCINE, NUVAXOVID, IN ADULTS: 20/05/2022 Further company coverage:


© Reuters 2022
All news about NOVAVAX, INC.
06/29Novavax to Participate in Vaccines and Related Biological Products Advisory Committee R..
AQ
06/29BioNTech, Pfizer to starting testing universal coronavirus vaccine in H2
RE
06/29Taiwan to receive first doses of Novavax COVID vaccine this week
RE
06/28Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Respo..
PR
06/28Novavax, Inc. Presents Data At FDA VRBPAC Meeting Demonstrates Broad Antibody Responses..
CI
06/28Serum Institute Of India's Covovax Has Been Approved By DCGI For Children Between The A..
RE
06/24Novavax COVID-19 Vaccine Nuvaxovid Recommended for Expanded Conditional Marketing Autho..
AQ
06/24Novavax Files Supplement to a New Drug Submission in Canada for Nuvaxovid COVID-19 Vacc..
AQ
06/24Novavax Nuvaxovid COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for U..
AQ
06/24The next COVID booster shots will likely be updated for Omicron
RE
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2022 4 274 M - -
Net income 2022 1 935 M - -
Net cash 2022 2 508 M - -
P/E ratio 2022 2,19x
Yield 2022 -
Capitalization 4 018 M 4 018 M -
EV / Sales 2022 0,35x
EV / Sales 2023 0,20x
Nbr of Employees 1 541
Free-Float 98,8%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 51,43 $
Average target price 151,86 $
Spread / Average Target 195%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-63.76%4 051
MODERNA, INC.-43.77%56 804
IQVIA HOLDINGS INC.-24.11%40 527
LONZA GROUP AG-33.77%39 234
SEAGEN INC.15.82%32 961
CELLTRION, INC.-9.85%18 726